AGSW(SH:600199) Xin Lang Cai Jing·2025-11-07 21:04Core Viewpoint - Anhui Jinzhongzi Liquor Co., Ltd. is transferring 92% equity of its subsidiary, Jin Taiyang Biochemical Pharmaceutical Co., Ltd., through a public listing, aiming to optimize its industrial structure and focus on core business development [1][5]. Group 1: Transaction Overview - The company has signed a property transaction contract with Shenzhen Jun Cheng Pharmaceutical Co., Ltd. for the transfer of 92% equity in Jin Taiyang Pharmaceutical [1][4]. - The transfer price is set at RMB 125,963,000, with a new transfer base price of 90% of the initial listing price to facilitate the transaction [3][5]. - The transaction adheres to principles of openness, fairness, and justice, with independent third-party asset evaluation ensuring fair pricing [5][7]. Group 2: Financial and Operational Impact - The transaction is expected to enhance the company's asset and resource utilization efficiency, aligning with its strategic goal of strengthening its core business and improving quality [5][7]. - The transfer will not significantly impact the company's operations or business development, ensuring no harm to the interests of the company and minority shareholders [5][7]. Group 3: Compliance and Documentation - The transaction has been approved by the company's board and the annual shareholders' meeting, confirming its compliance with regulatory requirements [7][8]. - Relevant documents, including the asset evaluation report and the property transaction contract, are available for review [6].